{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:53:43Z","timestamp":1768798423959,"version":"3.49.0"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.2169\/internalmedicine.4723-24","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T17:12:07Z","timestamp":1736874727000},"page":"2338-2343","source":"Crossref","is-referenced-by-count":3,"title":["Severe Hypocalcemia During JAK1\/2 Inhibitor Therapy for Myelofibrosis in a Patient with Liver Cirrhosis"],"prefix":"10.2169","volume":"64","author":[{"given":"Mayuna","family":"Kurumazaki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyoshi","family":"Ikejiri","sequence":"additional","affiliation":[{"name":"Okuizumo Town Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kanasaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Quint\u00e1s-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10: 127-140, 2011.","DOI":"10.1038\/nrd3264"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123: e123-e133, 2014.","DOI":"10.1182\/blood-2014-02-554634"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117, 2010.","DOI":"10.1182\/blood-2009-04-214957"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.","DOI":"10.1056\/NEJMoa1110556"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Maruotti N, Corrado A, Rotondo C, Cantatore FP. Janus kinase inhibitors role in bone remodeling. J Cell Physiol 235: 1915-1920, 2020.","DOI":"10.1002\/jcp.29149"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Matikainen N, Pekkarinen T, Ryh\u00e4nen EM, Schalin-J\u00e4ntti C. Physiology of calcium homeostasis: an overview. Endocrinol Metab Clin North Am 50: 575-590, 2021.","DOI":"10.1016\/j.ecl.2021.07.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 1092: 385-396, 2006.","DOI":"10.1196\/annals.1365.035"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96: 3540-3545, 1999.","DOI":"10.1073\/pnas.96.7.3540"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li J. JAK-STAT and bone metabolism. Jakstat 2: e23930, 2013.","DOI":"10.4161\/jkst.23930"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 64: 3531-3542, 2012.","DOI":"10.1002\/art.34649"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Murakami K, Kobayashi Y, Uehara S, et al. A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS One 12: e0181126, 2017.","DOI":"10.1371\/journal.pone.0181126"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 22: 216-224, 2011.","DOI":"10.1681\/ASN.2010020186"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-\u03baB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 26: 6453-6468, 2006.","DOI":"10.1128\/MCB.00356-06"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. O'Brien CA. Control of RANKL gene expression. Bone 46: 911-919, 2010.","DOI":"10.1016\/j.bone.2009.08.050"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gil \u00c1, Plaza-Diaz J, Mesa MD. Vitamin D: classic and novel actions. Ann Nutr Metab 72: 87-95, 2018.","DOI":"10.1159\/000486536"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gruson D, Buglioni A, Burnett JC Jr. PTH: potential role in management of heart failure. Clin Chim Acta 433: 290-296, 2014.","DOI":"10.1016\/j.cca.2014.03.029"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr Clin Pract 21: 273-278, 2006.","DOI":"10.1177\/0115426506021003273"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Posner DB, Russell RM, Absood S, et al. Effective 25-hydroxylation of vitamin D2 in alcoholic cirrhosis. Gastroenterology 74 (5 Pt 1): 866-870, 1978.","DOI":"10.1016\/0016-5085(78)90143-9"},{"key":"19","unstructured":"19. Ionele CM, Subtirelu MS, Ungureanu BS, Serbanescu MS, Rogoveanu I. Calcium and phosphorus deficiencies in patients with liver cirrhosis. Curr Health Sci J 48: 311-316, 2022."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Moutzouri E, Liberopoulos EN, Elisaf M. Life-threatening hypophosphataemia in a cirrhotic patient with jaundice. Arch Med Sci. Poland 7: 736-739, 2011.","DOI":"10.5114\/aoms.2011.24148"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ishimura E, Nishizawa Y, Inaba M, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 55: 1019-1027, 1999.","DOI":"10.1046\/j.1523-1755.1999.0550031019.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Baj J, Flieger W, Teresi\u0144ski G, et al. Magnesium, calcium, potassium, sodium, phosphorus, selenium, zinc, and chromium levels in alcohol use disorder: a review. J Clin Med 9: 2020.","DOI":"10.3390\/jcm9061901"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hall C, Nagengast AK, Knapp C, et al. Massive transfusions and severe hypocalcemia: an opportunity for monitoring and supplementation guidelines. Transfusion 61 Suppl 1: S188-S194, 2021.","DOI":"10.1111\/trf.16496"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-DeRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res 202: 182-187, 2016.","DOI":"10.1016\/j.jss.2015.12.036"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Byerly S, Inaba K, Biswas S, et al. Transfusion-related hypocalcemia after trauma. World J Surg 44: 3743-3750, 2020.","DOI":"10.1007\/s00268-020-05712-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Potestio CP, Van Helmond N, Azzam N, Mitrev LV, Patel A, Ben-Jacob T. The incidence, degree, and timing of hypocalcemia from massive transfusion: a retrospective review. Cureus 14: e22093, 2022.","DOI":"10.7759\/cureus.22093"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 31: 2450-2455, 2003.","DOI":"10.1097\/01.CCM.0000084871.76568.E6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ma Y, Xu Y, Chen F, Wang Y, Bai L, Tang H. Good tolerance of citrate accumulation due to plasma exchange among patients with acute-on-chronic liver failure: a prospective, observational study. Can J Gastroenterol Hepatol 2018: 4909742, 2018.","DOI":"10.1155\/2018\/4909742"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Chern JP, Lin KH. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Pediatr Hematol Oncol 24: 291-293, 2002.","DOI":"10.1097\/00043426-200205000-00014"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Jeong HK, An JH, Kim HS, et al. Hypoparathyroidism and subclinical hypothyroidism with secondary hemochromatosis. Endocrinol Metab (Seoul) 29: 91-95, 2014.","DOI":"10.3803\/EnM.2014.29.1.91"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Brent GA, LeBoff MS, Seely EW, Conlin PR, Brown EM. Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Metab 67: 944-950, 1988.","DOI":"10.1210\/jcem-67-5-944"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T, et al. Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK (V617F) mutation. Haematologica 98: 1517-1524, 2013.","DOI":"10.3324\/haematol.2012.082560"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Nechama M, Uchida T, Mor Yosef-Levi I, Silver J, Naveh-Many T. The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Invest 119: 3102-3114, 2009.","DOI":"10.1172\/JCI39522"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Zhao Y, Chen P, Dou L, et al. Co-administration with voriconazole doubles the exposure of ruxolitinib in patients with hematological malignancies. Drug Des Devel Ther 16: 817-825, 2022.","DOI":"10.2147\/DDDT.S354270"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 13 Suppl 3: 27-36, 1999.","DOI":"10.1046\/j.1365-2036.1999.00022.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4723-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:15:58Z","timestamp":1754108158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4723-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":35,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4723-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"4723-24"}}